XML 13 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Income Statement [Abstract]    
Net sales $ 5,238,604 $ 1,218,862
Cost of sales 1,946,055 247,772
Gross Profit 3,292,549 971,090
Operating expenses    
Compensation and related expenses 1,247,195 532,421
Professional fees 477,401 114,890
Marketing expenses 1,710,357 230,661
Research and development expenses 23,925
General and administrative expenses 1,032,278 331,410
Total operating expenses 4,467,231 1,233,307
Operating (Loss) (1,174,682) (262,217)
Gain on sale of Adiuvo Investment S.A. stock 127,261
Interest (expense) (48,611) (37,476)
Net Income (Loss) Before Taxes (1,223,293) (172,432)
Deferred income tax benefit 13,200
Net (Loss) (1,223,293) (159,232)
Net (loss) attributable to noncontrolling interests (115,749) (97,240)
Net (loss) attributable to Immudyne, Inc. $ (1,107,544) $ (61,992)
Basic and diluted (loss) per share attributable to Immudyne, Inc. $ (0.03) $ 0.00
Average number of common shares outstanding    
Basic 33,478,229 30,810,000
Diluted 33,478,229 30,810,000